Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis

BACKGROUND: Pimavanserin is approved for treatment of Parkinson disease (PD)-related psychosis, but its use has been associated with an increased risk of death during clinical trials, as well as during postmarketing surveillance. Previous reports on the association between pimavanserin and mortality...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Joshua D, Cicali, Brian, Henriksen, Carl, Malaty, Irene, Okun, Michael S, Armstrong, Melissa J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391001/
https://www.ncbi.nlm.nih.gov/pubmed/34057395
http://dx.doi.org/10.18553/jmcp.2021.27.6.785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391001/
https://www.ncbi.nlm.nih.gov/pubmed/34057395
http://dx.doi.org/10.18553/jmcp.2021.27.6.785

Ejemplares similares